Key statistics
As of last trade Beigene Ltd (6160:HKG.HZ) traded at 119.00, -7.10% below its 52-week high of 128.10, set on Sep 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 119.30 |
---|---|
High | 121.40 |
Low | 117.50 |
Bid | 119.00 |
Offer | 119.20 |
Previous close | 119.60 |
Average volume | 1.64m |
---|---|
Shares outstanding | 1.38bn |
Free float | 1.31bn |
P/E (TTM) | -- |
Market cap | 170.25bn HKD |
EPS (TTM) | -3.04 HKD |
Data delayed at least 15 minutes, as of Sep 19 2024 06:29 BST.
More ▼
Press releases
- BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
- BeiGene Announces Updates to Commercial Leadership Team
- BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
- BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
- BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
- BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
- BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
More ▼